President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourKyle Diamantas <1%
Stephen Hahn <1%
Brett Giroir <1%
Grace Graham <1%
$39,291 Vol.
$39,291 Vol.
30 déc. 2026
Kyle Diamantas
Non
Stephen Hahn
Non
Brett Giroir
Non
Grace Graham
Non
Sara Brenner
Non
Aucune annonce d'ici le 31 décembre
Non
Kyle Diamantas <1%
Stephen Hahn <1%
Brett Giroir <1%
Grace Graham <1%
$39,291 Vol.
$39,291 Vol.
30 déc. 2026
Kyle Diamantas
$10,368 Vol.
Non
Stephen Hahn
$5,255 Vol.
Non
Brett Giroir
$5,265 Vol.
Non
Grace Graham
$6,713 Vol.
Non
Sara Brenner
$8,024 Vol.
Non
Aucune annonce d'ici le 31 décembre
$3,664 Vol.
Non
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Marché ouvert : May 12, 2026, 7:59 PM ET
Volume
$39,291Date de fin
31 déc. 2026Marché ouvert
May 12, 2026, 7:59 PM ETRésolveur
0x69c47De9D...Résultat proposé: Non
Aucune contestation
Résultat final: Non
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$39,291Date de fin
31 déc. 2026Marché ouvert
May 12, 2026, 7:59 PM ETRésolveur
0x69c47De9D...Résultat proposé: Non
Aucune contestation
Résultat final: Non
President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes